Navigation Links
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Date:11/15/2012

them," said Andreas Koester, MD, PhD, Head, Clinical Trial Innovation/External Alliances, Janssen Research & Development. "We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives." 

Earlier this year, Janssen joined nine other companies to launch TransCelerate BioPharma Inc. ("TransCelerate"), the largest initiative of its kind, which aims to identify and overcome common drug development challenges in order to improve the quality of clinical studies and to bring new medicines to patients faster. The initiative identified the centralization of site prequalification and training as one of five key projects, and the Janssen-led Investigator Databank project will serve as a foundation for the TransCelerate initiative.

"Industry collaboration, including pre-competitive data sharing, is critical to ensuring continued progress to improve industry-wide clinical trial practices," said newly appointed CEO of TransCelerate BioPharma, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate Vice President, Science & Technology, Johnson & Johnson. "This work is aligned with TransCelerate's initial focus on clinical study execution and we encourage participation from our founding TransCelerate companies to solve industry-wide challenges in a collaborative environment." 

Member companies of TransCelerate who wish to join the Investigator Databank will automatically qualify for participation. It is anticipated that the Investigator Databank will be operational by the end of the year and incorporated into one of the priority projects within TransCelerate by mid-2013.

The Investigator Databank will be hosted by DrugDev.org, an independent, third pa
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Nektar Therapeutics (NASDAQ: NKTR ) today ... research scientists at the company,s existing San Francisco ... the UCSF research and medical campus in Mission ... Huntsville, Alabama research site will be relocating to ...
... NEW YORK, March 20, 2012 Reportlinker.com ... is available in its catalogue: ... Global Market Analysis, Size, Share & Forecast ... http://www.reportlinker.com/p0797075/Magnetic-Resonance-Imaging-MRI-Market-Global-Market-Analysis-Size-Share--Forecast-2012---2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Description ...
Cached Medicine Technology:Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 2Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 3Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 4Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 5Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 2Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 3Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 4
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... , ... has established a strong link between elevated commitment among employees and positive business outcomes. ... Charlotte, NC ... host a webinar titled “Building Workforce Commitment.” The free hour-long webinar will be ...
... ... clients, connecting them with the best-in-class partners around the world, delivering the ultimate experience ... ... a different connotation today than the decades old call center depiction. Clients today ...
... Hospitals ... use” of certified Electronic Medical Record (EMR) systems under the American Recovery and Reinvestment ... ... (ARRA) hospitals and physicians can receive $19 billion in subsidies over five years for ...
... ... SEO firm in 2001 under the name of Anna Tulchinsky Web Consultancy, Joomla Bliss was ... quality or professionalism. The firm is offering several website design + SEO packages tailored specifically ... , ...
... , ... on Interferential mode, is reducing the severity, duration and frequency of pain for many patients ... weeks between treatments. , ... March 9, 2010 -- The Infrex Plus Unit from MedFaxx, when used on Interferential Mode, ...
... ... ... , ... ...
Cached Medicine News:Health News:Morehead Webinar to Discuss Building Workforce Commitment 2Health News:Announcing the Evolution of Provider Placement Methodology – EPIC Connections 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 3Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 2Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 2Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 2Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 3Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 5Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 6Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 7Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 8Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: